TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06372457

Intervention type: DRUG
Intervention: Approved Hypertrophic Cardiomyopathy drug treatments
Description: As per product label

Intervention type: DRUG
Intervention: Mavacamten
Description: As per product label
Study: NCT05274126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient group/Passvers
Description: Passvers intervention aims at :~* helping patients followed in the centers, presenting a Severe and Persistent Mental Disorder (schizophrenia, mood disorder, autism spectrum disorder, etc.), at risk or in a situation of psychological disability, to enroll in a rehabilitation program towards recovery.~* supporting the emergence and construction of projects by the people themselves, and to accompany them to realize them.~* Encouraging the use of resources in their environment and common law mechanisms (city hall, department, associations, etc.) for better social integration.~* encouraging involvement in care understood as useful tools for the realization of the personal project.~Passvers also aims at :~* promoting a change in professional practices within the team, in favor of recovery-oriented practices based on the concept of engagement or empowerment.~* allowing cooperation between health and social structures aiming at destigmatizing mental illness.
Study: NCT05662592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Broadband Light
Description: Broadband Light device will be used for treatment of pigmented skin lesions
Study: NCT04551261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS4
Description: It is a new dihydropyrimidine antiviral drug that interferes the assembly of HBV core granule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS4
Description: It is a new dihydropyrimidine antiviral drug that interferes the assembly of HBV core granule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: 1. It is HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection;~2. It is a CYP3A inhibitor combined with other drug to increase the exposure in human.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: 1. It is HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection;~2. It is a CYP3A inhibitor combined with other drug to increase the exposure in human.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: It is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: It is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
Study: NCT05247463

Intervention type: OTHER
Intervention: Increase in upper age of eligibility for breast cancer screening from 64 to 70
Description: The upper age limit of eligibility for Breast Cancer Screening increased in England from 64 to 70 as a result of the NHS Cancer Plan, so women were offered an additional 2 rounds of screening.

Intervention type: OTHER
Intervention: Screening round length
Description: The target round length (frequency) of breast cancer screening in England is every 3 years. However in practice there is variability in this due to local centre capacity. The exposures are round lengths of approximately 2 years and approximately 3 years

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening test threshold
Description: Radiologists and equivalent health professionals examine women's screening mammograms for potential signs of cancer, and recall some women for further diagnostic tests. Each has a different test threshold for recall, characterised by the proportion of previous cases that they have recalled.
Study: NCT05538481

Intervention type: OTHER
Intervention: Semi-structured interview
Description: A collection of individual cultural values and palliative care preferences within the focus group meetings

Intervention type: OTHER
Intervention: Developed survey completion
Description: A collection of individual responses to a survey created after focus group completion and analysis

Intervention type: OTHER
Intervention: Systems of Belief Inventory (SBI-15R)
Description: A 15-item questionnaire designed to measure religious and spiritual beliefs and practices and the social support derived from a community sharing those beliefs.

Intervention type: OTHER
Intervention: Systems of Belief Inventory (SBI-15R)
Description: A 15-item questionnaire designed to measure religious and spiritual beliefs and practices and the social support derived from a community sharing those beliefs.
Study: NCT05718648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550
Study: NCT06278077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurexan
Description: The active ingredients are Passiflora incarnata Dil. D2 (0.6 mg / tablet), Avena sativa Dil. D2 (0.6 mg / tablet), Coffea arabica Dil. D12 (0.6 mg/tablet) and Zincum isovalerianicum Dil. D4 (0.6 mg / tablet). Inactive excipients are lactose monohydrate and magnesium stearate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains lactose monohydrate, magnesium stearate and looks identical to Neurexan in terms of taste, size, color and labelling.
Study: NCT05959980

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior cervical fixation surgery
Description: These patients will undergo posterior cervical fixation in the form of cervical lateral mass screw fixation in extension without decompression under general anesthesia.
Study: NCT04875247

Intervention type: DEVICE
Intervention: IOLMaster 700 with central topography
Description: The time needed to perform the measurement using the IOLMaster700 equipment with central topography will be recorded.

Intervention type: DEVICE
Intervention: IOLMaster 700 without central topography plus Cassini
Description: The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Cassini equipment will be recorded.

Intervention type: DEVICE
Intervention: IOLMaster 700 without central topography plus Pentacam
Description: The time needed to perform the measurement using the IOLMaster700 equipment without central topography plus the Pentacam equipment will be recorded.
Study: NCT05179941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion with Indocyanine green
Description: Infusion of Indocyanine green to determine perfusion of the subscapularis tendon change after tenotomy vs peel technique and subsequent intra-operative repair.
Study: NCT06275672

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted version of the mhGAP-IG
Description: An Ugandan adapted version of the mhGAP-IG CAMH module for identification, assessment, and management of common mental disorders in children and adolescents. The mhGAP-IG CAMH module further details six different protocols for the management of these mental health problems, primarily based on psychosocial and systemic interventions. The described psychosocial interventions can also be provided as general prevention for children with subclinical problems. Lastly, the module guides further follow-up assessment. Experts identified by the Ministry of Health will train trainers who train and follow-up teachers and health personnel receiving the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted version of the mhGAP-IG
Description: An Ugandan adapted version of the mhGAP-IG CAMH module for identification, assessment, and management of common mental disorders in children and adolescents. The mhGAP-IG CAMH module further details six different protocols for the management of these mental health problems, primarily based on psychosocial and systemic interventions. The described psychosocial interventions can also be provided as general prevention for children with subclinical problems. Lastly, the module guides further follow-up assessment. Experts identified by the Ministry of Health will train trainers who train and follow-up teachers and health personnel receiving the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted version of the mhGAP-IG
Description: An Ugandan adapted version of the mhGAP-IG CAMH module for identification, assessment, and management of common mental disorders in children and adolescents. The mhGAP-IG CAMH module further details six different protocols for the management of these mental health problems, primarily based on psychosocial and systemic interventions. The described psychosocial interventions can also be provided as general prevention for children with subclinical problems. Lastly, the module guides further follow-up assessment. Experts identified by the Ministry of Health will train trainers who train and follow-up teachers and health personnel receiving the intervention.
Study: NCT05963321

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TDCS
Description: Two tDCS devices will be used simultaneously. The intervention consists of a tDCS session in which the active electrode will be located in the cerebellum and/or in the primary motor cortex (4 stimulation protocols that will be implemented; active cerebellum electrode and active M1 electrode, sham cerebellum electrode and active M1 electrode, active cerebellum and sham M1 electrode, sham cerebellar electrode and sham M1 electrode) and the cathode in the contralateral supraorbital region.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TDCS
Description: Two tDCS devices will be used simultaneously. The intervention consists of a tDCS session in which the active electrode will be located in the cerebellum and/or in the primary motor cortex (4 stimulation protocols that will be implemented; active cerebellum electrode and active M1 electrode, sham cerebellum electrode and active M1 electrode, active cerebellum and sham M1 electrode, sham cerebellar electrode and sham M1 electrode) and the cathode in the contralateral supraorbital region.
Study: NCT06275672

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted version of the mhGAP-IG
Description: An Ugandan adapted version of the mhGAP-IG CAMH module for identification, assessment, and management of common mental disorders in children and adolescents. The mhGAP-IG CAMH module further details six different protocols for the management of these mental health problems, primarily based on psychosocial and systemic interventions. The described psychosocial interventions can also be provided as general prevention for children with subclinical problems. Lastly, the module guides further follow-up assessment. Experts identified by the Ministry of Health will train trainers who train and follow-up teachers and health personnel receiving the intervention.
Study: NCT05963321

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TDCS
Description: Two tDCS devices will be used simultaneously. The intervention consists of a tDCS session in which the active electrode will be located in the cerebellum and/or in the primary motor cortex (4 stimulation protocols that will be implemented; active cerebellum electrode and active M1 electrode, sham cerebellum electrode and active M1 electrode, active cerebellum and sham M1 electrode, sham cerebellar electrode and sham M1 electrode) and the cathode in the contralateral supraorbital region.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TDCS
Description: Two tDCS devices will be used simultaneously. The intervention consists of a tDCS session in which the active electrode will be located in the cerebellum and/or in the primary motor cortex (4 stimulation protocols that will be implemented; active cerebellum electrode and active M1 electrode, sham cerebellum electrode and active M1 electrode, active cerebellum and sham M1 electrode, sham cerebellar electrode and sham M1 electrode) and the cathode in the contralateral supraorbital region.
Study: NCT06275672

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted version of the mhGAP-IG
Description: An Ugandan adapted version of the mhGAP-IG CAMH module for identification, assessment, and management of common mental disorders in children and adolescents. The mhGAP-IG CAMH module further details six different protocols for the management of these mental health problems, primarily based on psychosocial and systemic interventions. The described psychosocial interventions can also be provided as general prevention for children with subclinical problems. Lastly, the module guides further follow-up assessment. Experts identified by the Ministry of Health will train trainers who train and follow-up teachers and health personnel receiving the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted version of the mhGAP-IG
Description: An Ugandan adapted version of the mhGAP-IG CAMH module for identification, assessment, and management of common mental disorders in children and adolescents. The mhGAP-IG CAMH module further details six different protocols for the management of these mental health problems, primarily based on psychosocial and systemic interventions. The described psychosocial interventions can also be provided as general prevention for children with subclinical problems. Lastly, the module guides further follow-up assessment. Experts identified by the Ministry of Health will train trainers who train and follow-up teachers and health personnel receiving the intervention.
Study: NCT04430569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Alteplase single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single intravenous infusion of 0.6 mg/kg of estimated bodyweight with a maximum of 50 mg given over 15 minutes.
Study: NCT06225609

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ghost ileostomy
Description: Laparoscopic or robotic surgery with ghost ileostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No ileostomy
Description: Laparoscopic or robotic surgery with no ileostomy
Study: NCT05902702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nebulized isotonic saline
Description: The intervention will constitute nebulized isotonic saline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal irrigation with isotonic saline
Description: The intervention will constitute isotonic saline administered as nasal drops.
Study: NCT05681130

Intervention type: OTHER
Intervention: questionaire
Description: two questionaires for each group

Intervention type: OTHER
Intervention: questionaire
Description: two questionaires for each group
Study: NCT06013618

Intervention type: DRUG
Group type: OTHER
Intervention: Naxitamab monotherapy
Description: Naxitamab is administered on days 1, 3, and 5

Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF
Description: Each treatment cycle is 28 days and is started with five days (days -4 to 0) of GM-CSF administered at 250 mcg/m2/day in advance of the start of naxitamab infusion. GM-CSF is thereafter administered at 500 mcg/m2/day on days 1 to 5.

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Each HITS treatment cycle is 21 days. Irinotecan intravenously (IV) at 50 mg/m2/day will be administered from Day 1-5 concurrently with temozolomide orally at 150 mg/m2/day or 100 mg/m2/day.

Intervention type: DRUG
Group type: OTHER
Intervention: Naxitamab in combination therapy
Description: Naxitamab 2.25mg/kg IV will be administered on Days 2, 4, 8 and 10.

Intervention type: DRUG
Group type: OTHER
Intervention: Naxitamab in combination therapy
Description: Naxitamab 2.25mg/kg IV will be administered on Days 2, 4, 8 and 10.

Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF with combination regimen
Description: GM-CSF 250 mcg/m2/day will be administered subcutaneously on Days 6-10.
Study: NCT05897814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Location of the epidural analgesia catheter
Description: Research of the location of the epidural analgesia catheter using M-mode and color Doppler (cD) ultrasonography.
Study: NCT06318884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCTB35 injection
Description: SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and another appropriate dose of SCTB35 will be applied for the dose-expansion cohorts.
Study: NCT04326530

Intervention type: DEVICE
Intervention: Pneumopipe® (European patent 12425057.2, Rome, Italy)
Description: Collection of VOCs on a cartridge after that the child has normally breathed in it for 3 min, both at the baseline and at the last visit.

Intervention type: OTHER
Intervention: Other assessments
Description: * Spirometry, both at the baseline and at the last visit.~* 24-hour urine collection, both at the baseline and at the last visit.
Study: NCT06013618

Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF with combination regimen
Description: GM-CSF 250 mcg/m2/day will be administered subcutaneously on Days 6-10.

Intervention type: DRUG
Group type: OTHER
Intervention: Sintilimab
Description: Sintilimab was administerd with 3mg/kg (max 200mg) on day 11 every 3 weeks.
Study: NCT06052748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-223A
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-223A
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-223B
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-223B
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-223C
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-223A Placebo
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-223A Placebo
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-223B Placebo
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-223B Placebo
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-223C Placebo
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-223C Placebo
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-223C Placebo
Description: PO, Once daily(QD), 8weeks
Study: NCT05733455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)
Description: Participants will ingest two overencapsulated tablets of alpelisib at 23:00, along with a saltine cracker.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (microcrystalline cellulose), 2 capsules
Description: Participants will ingest two capsules filled with microcrystalline cellulose at 23:00, along with a saltine cracker.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Pro
Description: Continuous glucose monitoring for 24 hours (double blinded)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: FreeStyle Libre Pro
Description: Continuous glucose monitoring for 24 hours (double blinded)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT) with Trutol glucose beverage
Description: Participants will drink Trutol glucose beverage (D-glucose 75 g in 10 fl oz) and blood will be sampled at baseline and at 15, 30, 60, 90, 120, 150, and 180 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Oral glucose tolerance test (OGTT) with Trutol glucose beverage
Description: Participants will drink Trutol glucose beverage (D-glucose 75 g in 10 fl oz) and blood will be sampled at baseline and at 15, 30, 60, 90, 120, 150, and 180 minutes.
Study: NCT06528561

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sef-care program with exercise
Description: Self-care program with physical exercise with aerobic and muscular strength components implemented progressively according to the participant's clinical evolution
Study: NCT05932524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 MG
Description: Baricitinib 2 mg q.d., p.o., for 6 consecutive months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 40 mg q.d. for 4 consecutive days (the 4-day course of dexamethasone will be repeated in the case of lack of response by day 10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg q.d. for 4 consecutive days (the 4-day course of dexamethasone will be repeated in the case of lack of response by day 10)